News & Updates

Ustekinumab vs vedolizumab for older IBD patients: MACE not different, but mortality lower
Ustekinumab vs vedolizumab for older IBD patients: MACE not different, but mortality lower
28 Feb 2025 byJairia Dela Cruz

In the real-world treatment of older adults with inflammatory bowel disease (IBD), the cardiovascular safety of ustekinumab is similar to that of vedolizumab, with no significant difference in the risk of major adverse cardiovascular events (MACE). However, ustekinumab is associated with a reduced risk of all-cause mortality.

Ustekinumab vs vedolizumab for older IBD patients: MACE not different, but mortality lower
28 Feb 2025